Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000892920 | SCV001036827 | likely benign | not provided | 2024-12-04 | criteria provided, single submitter | clinical testing | |
Fulgent Genetics, |
RCV002501476 | SCV002801746 | likely benign | B4GALT1-congenital disorder of glycosylation | 2021-12-08 | criteria provided, single submitter | clinical testing | |
Women's Health and Genetics/Laboratory Corporation of America, |
RCV003317397 | SCV004020844 | uncertain significance | not specified | 2023-06-07 | criteria provided, single submitter | clinical testing | Variant summary: B4GALT1 c.259C>T (p.Pro87Ser) results in a non-conservative amino acid change in the encoded protein sequence. Four of five in-silico tools predict a benign effect of the variant on protein function. The variant allele was found at a frequency of 0.00028 in 186338 control chromosomes, with increased frequency in populations of African descent (0.0044 in 10762 control chromosomes). To our knowledge, no occurrence of c.259C>T in individuals affected with B4GALT1-CDG and no experimental evidence demonstrating its impact on protein function have been reported. Two clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014 without evidence for independent evaluation. Both laboratories classified the variant as likely benign. Based on the evidence outlined above, the variant was classified as uncertain significance. |
Breakthrough Genomics, |
RCV000892920 | SCV005224146 | likely benign | not provided | criteria provided, single submitter | not provided |